Lipid-based nanocarriers for breast cancer treatment – comprehensive review. . ???aop.label???. doi: 10.3109/10717544.2015.1092183

Nanotechnology has brought a revolution in the field of science, which has subsequently lead to development of novel dosage forms such as niosomes, liposomes and proniosomes. Proniosomes overcome the demerits involved with niosomal and liposomal drug delivery systems. Proniosomes are liquid crystalline compact niosome hybrids which upon hydration form niosomes. They help in reducing physical stability problems involved with niosomes such as leaking, fusion, aggregation and provide convenience in dosing, distribution, transportation and storage showing improved results than conventional niosomes. This review focuses on different aspects of proniosome such as preparation, characterization, drug release, applications, merits, demerits, present scenario in market and future trends.

Background: Diabetic foot ulcer is one of the major causes of mortality in diabetic patients. Very few drugs and therapies have regulatory approval for this indication and several agents from diverse pharmacological classes are currently in various phases of clinical trials for the management of diabetic foot ulcers.Scope: The purpose of this review is to provide concise information of the drugs and therapies which are approved and present in clinical trials.Review Methods: This review was carried out by systematic searches of relevant guidelines, patents, published articles, reviews and abstracts in PubMed/Medline, Web of Science, clinicaltrials.gov, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and Google Scholar of all English language articles are considered as of 01 March 2015.The following search terms were used: Diabetes, Diabetic foot, Diabetic foot ulcer, Diabetic wound, Diabetic foot infections, wound management, randomized controlled trials, App...